Polycystic Ovary SyndromeNCT04960982
Changes in Pregnancy in Egyptian Women With History of Recurrent Miscarriage
An observational study of Polycystic Ovary Syndrome, run by Kafrelsheikh University at 1 site in Egypt.
Trial summary
Introduction: Elevated levels of androgen and insulin-resistant have been implicated in recurrent miscarriage in women with PCOS. Published data are scarce on androgen level and cervical length of women with and without PCOS and a history of miscarriage. Read more about this study
- Who is it for?
- Ages 23 to 40 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Polycystic Ovary Syndrome
- What is being tested?
- blood test
- How many people
- 40 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Mar 2018to 1 May 2021
- How long will I take part?
- 9 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 23 to 40 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Egyptian women
Who may be able to join
None listed.
Who cannot join
- Any other diagnosed medical condition link with increased risk of miscarriage, including thyroid status and gestational diabetes
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Changes in Testosterone, SHBG, DHEA and Cervical Length During Pregnancy in Egyptian Women With History of Recurrent Miscarriage
Introduction: Elevated levels of androgen and insulin-resistant have been implicated in recurrent miscarriage in women with PCOS. Published data are scarce on androgen level and cervical length of women with and without PCOS and a history of miscarriage.
Aim: The aim of this study was to investigate the levels of testosterone (TT), Sex Hormone Binding Globulin (SHBG), Dehyroepiandrostenedione (DHEA) and cervical length in Egyptian women with and without history PCOS and history of RM during pregnancy .
Method: Pregnant women with (n=38) and without (n=40) PCOS and history of recurrent miscarriages were recruited from the Obstetrics Department, Alagoza Hospital, Cairo, Egypt. Healthy pregnant women without PCOS and history of RM (n=40, HC) were also recruited. TT, SHBG,DHEA and Sex Hormone Binding Globulin (SHBG) level and cervical length were assessed at first, second and the third trimester or at the start of miscarriage
Read the detailed description
Introduction
Recurrent miscarriage (RM )is defined as the loss of three of more consecutive pregnancies before 20 weeks gestation (Royal College of Obstetricians \& Gynaecologists 2011, Practice Committee of American Society for Reproductive Medicine 2013). The prevalence of RM varies from country to country and within communities within the country. It tends to be higher in developing countries. However it effects 1% to 2%of women (Jeve et al., 2014, Green-top Guideline No. 17).Other studies have reported incidences of RM between 0.5% and 2.3 % (Christiansen et al.,2007, Stirrat et al., 1990, Alberman et al., 1988).
Currently the established risk factors of RM include hormonal associated conditions (Stephenson et al.,1996, Fox-Lee et al., 2007) , uterine abnormalities (including adhesions post-surgery) (Rimbizis et al.,2001, Salim et al.,2003) anti-phospholipid syndrome Thrombotic (Greer et al., 2003) , chromosomal and genetic (Braekeleer et al., 1990 , Clifford et al.,1994, Stephenson et al., 2006, Franssen et al., 2006) conditions .Indeed some researchers consider PCOS as a risk factor, However some don't.
Approximately 8% to 12% of RM is due to endocrine causes mainly due to hyperandrogenism and hyperinsulinemia in PCOS (Smith et al., 2011, Witchel et al., 2019, Rai et al., 2000) . Little research focuses directly on the effect of PCOS during gestation and how that can be linked to poor pregnancy outcomes. However, there is a positive correlation between increased risk of miscarriage and hyperhomocysteinemia in insulin resistant patients, a common component of PCOS (Chakraborty et al.,2013).
The current literature providing conflicting views on androgen levels effecting pregnancy in PCOS patients some clarity is required as to whether its elevation impacts pregnancy. Not only that, but the is limited published data which compared the androgen and cervical length at different gestational periods of women with history of miscarriage either due to PCOS or for unknown reasons.
Cervical cerclage (CC) is one of the management options offered to patient who has history of midterm miscarriage. The efficacy of CC in management is still doubtable.
Aim The aim of this study was to investigate the levels of testosterone (TT), Sex Hormone Binding Globulin (SHBG), Dehyroepiandrostenedione (DHEA) and cervical length in women with and without history PCOS and history of RM during pregnancy .
Subjects and Methods
- Subjects
Participants of the study are women with (n=38) and without PCOS (n=40) and history of RM were recruited during their first antenatal visit from Al-Agoza Hospital, Cairo, Egypt. They were recruited during their first antenatal visit. Similarly pregnant women without PCOS (n=40) with no history of RM were recruited. Detailed demographic, medical and obstetric history was documented.
The inclusion criteria for the study were women aged 23 to 40 years at the time of enrolment into the study. The exclusion criteria for all participants included any other diagnosed medical condition link with increased risk of miscarriage, including thyroid status and gestational diabetes. All participants examined at the time of recruitment.
The control group were matched for age and BMI with no previous history of RM.
This study was conducted in line with the human experimentation guidelines, dictated by the Helsinki declaration. The procedures used were approved by local ethical committee and conducted in line with the practices of Al-Agoza Hospital, Cairo, Egypt. All patients within the study were briefed on the procedures and protocol that would take place and written consent was obtained before induction into the study.
- Methods
Confirmation of the pregnancy was made by beta-human chorionic gonadotrophin (Bhcg ) plus ultrasound scan and clinical history in case of miscarriage.
Diagnosis for patients with recurrent miscarriage was in concordance with the guidelines defined by the Royal College of Obstetricians and Gynaecologists; the loss of three or more consecutive pregnancies (Royal College of Obstetricians \& Gynaecologists 2011 ).The diagnosis of PCOS was based on Rotterdam 2003 Criteria (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004 ) which require two of the following; Oligo- or anovulation, Clinical and/or biochemical signs of hyperandrogenism or Polycystic ovaries and exclusion of other related disorders.
Blood Samples were collected by a professional trained in phlebotomy at the time points ; first, second and the third trimester or at the start of miscarriage .Samples were analysed for TT, SHBG,SHBG and DHEA using The ADVIA Centaur® XPT Immunoassay System - Siemens (https://www.siemens-healthineers.com/en-uk/immunoassay/systems/advia-centaur-xpt#TECHNICAL_SPECIFICATIONS).This system is easy to use where samples and reagents which could be loaded or without pausing the system. Also it doesn't require daily set up procedure and implement new assays immediately with one easy scan of a test definition bar code.
It requires 10-200 μL per test. it offers Automatic dilution varies by assay, up to 1:2500. The reagent capacity on board is 30 assays.
Similarly, cervical length was also measured at first, second and the third trimester or at the start of miscarriage .It was measured via transvaginal ultrasound (Berghella et al.,1997). The Voluson™ E8 ultrasound system is used for this study (https://www.gehealthcare.com/products/ultrasound/voluson/voluson-e8 ). The data was recorded by measuring the distance between the external os of the cervix and to where the cervix is closed defined by the apex of the funnelling of the membranes (Berghella et al., 1997) .
All patients within the RM groups attended cerclage treatment during the second trimester, this included elective and emergency elective procedures. Patients presented at the time of delivery or for recording of miscarriage where gestational age, gender of the fetus/baby and whether it was a live birth was noted.
- Conditions
- Polycystic Ovary Syndrome
- Being tested
- blood test
- Keywords
- PCOS Recurrent Miscarriage
- Medical subject headings
- Polycystic Ovary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood testDiagnostic test
blood sample is taken in first, second and third trimester of pregnancy
| Study group | Role | What they receive |
|---|---|---|
| PCOS-RM | PCOS women with history of RM Receives: Diagnostic Test: blood test | |
| Non PCOS RM | Non PCOS women with history of RM Receives: Diagnostic Test: blood test | |
| Control | women with no history of RM Receives: Diagnostic Test: blood test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cervical length changes during pregnancy
Cervical length is shorter in recurrent miscarriage groups at the start of the study and getting shorter during pregnancy
Measured: 9 months
Androgens changes during pregnancy
TT, SHBG,DHEA and Sex Hormone Binding Globulin (SHBG) level were assessed at first, second and the third trimester or at the start of miscarriage
Measured: 9 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2021
- Study start1 Mar 2018
- Primary completion1 Sep 2020
- Study completion1 May 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Polycystic Ovary SyndromeStudies of the same condition, open and under way.
- More trials run by Kafrelsheikh UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 40 participants (actual)
- Target duration
- 9 Months
Sponsor and investigators
- Lead sponsor
- Kafrelsheikh University
- Sponsor type
- University, hospital or other
- Collaborators
- London Metropolitan University
- Responsible party
- Principal investigator, Dr Essam El Mahdi, Kafrelsheikh University
- Investigators
- Essam El Mahdi, MD, Principal investigator, London Metropolitan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04960982
- Sponsor's protocol ID
- 'RMPCOS2021
- Status last verified
- Jul 2021
- First submitted
- 9 Jul 2021
- Last updated
- 14 Jul 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: when study complited we will decide
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Changes in Testosterone, SHBG, DHEA and Cervical Length During Pregnancy in Egyptian Women With History of Recurrent Miscarriage
- ClinicalTrials.gov ID
- NCT04960982
- Acronym / sponsor ID
- 'RMPCOS2021
- Conditions
- Polycystic Ovary Syndrome
- Keywords
- PCOS Recurrent Miscarriage
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Kafrelsheikh UniversityUniversity, hospital or other
- Collaborators
- London Metropolitan University
- Study start
- 1 Mar 2018 (actual)
- Primary completion
- 1 Sep 2020 (actual)
- Study completion
- 1 May 2021 (actual)
- First posted
- 14 Jul 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Introduction: Elevated levels of androgen and insulin-resistant have been implicated in recurrent miscarriage in women with PCOS. Published data are scarce on androgen level and cervical length of women with and without PCOS and a history of miscarriage.
Aim: The aim of this study was to investigate the levels of testosterone (TT), Sex Hormone Binding Globulin (SHBG), Dehyroepiandrostenedione (DHEA) and cervical length in Egyptian women with and without history PCOS and history of RM during pregnancy .
Method: Pregnant women with (n=38) and without (n=40) PCOS and history of recurrent miscarriages were recruited from the Obstetrics Department, Alagoza Hospital, Cairo, Egypt. Healthy pregnant women without PCOS and history of RM (n=40, HC) were also recruited. TT, SHBG,DHEA and Sex Hormone Binding Globulin (SHBG) level and cervical length were assessed at first, second and the third trimester or at the start of miscarriage
Detailed description
Introduction
Recurrent miscarriage (RM )is defined as the loss of three of more consecutive pregnancies before 20 weeks gestation (Royal College of Obstetricians \& Gynaecologists 2011, Practice Committee of American Society for Reproductive Medicine 2013). The prevalence of RM varies from country to country and within communities within the country. It tends to be higher in developing countries. However it effects 1% to 2%of women (Jeve et al., 2014, Green-top Guideline No. 17).Other studies have reported incidences of RM between 0.5% and 2.3 % (Christiansen et al.,2007, Stirrat et al., 1990, Alberman et al., 1988).
Currently the established risk factors of RM include hormonal associated conditions (Stephenson et al.,1996, Fox-Lee et al., 2007) , uterine abnormalities (including adhesions post-surgery) (Rimbizis et al.,2001, Salim et al.,2003) anti-phospholipid syndrome Thrombotic (Greer et al., 2003) , chromosomal and genetic (Braekeleer et al., 1990 , Clifford et al.,1994, Stephenson et al., 2006, Franssen et al., 2006) conditions .Indeed some researchers consider PCOS as a risk factor, However some don't.
Approximately 8% to 12% of RM is due to endocrine causes mainly due to hyperandrogenism and hyperinsulinemia in PCOS (Smith et al., 2011, Witchel et al., 2019, Rai et al., 2000) . Little research focuses directly on the effect of PCOS during gestation and how that can be linked to poor pregnancy outcomes. However, there is a positive correlation between increased risk of miscarriage and hyperhomocysteinemia in insulin resistant patients, a common component of PCOS (Chakraborty et al.,2013).
The current literature providing conflicting views on androgen levels effecting pregnancy in PCOS patients some clarity is required as to whether its elevation impacts pregnancy. Not only that, but the is limited published data which compared the androgen and cervical length at different gestational periods of women with history of miscarriage either due to PCOS or for unknown reasons.
Cervical cerclage (CC) is one of the management options offered to patient who has history of midterm miscarriage. The efficacy of CC in management is still doubtable.
Aim The aim of this study was to investigate the levels of testosterone (TT), Sex Hormone Binding Globulin (SHBG), Dehyroepiandrostenedione (DHEA) and cervical length in women with and without history PCOS and history of RM during pregnancy .
Subjects and Methods
- Subjects
Participants of the study are women with (n=38) and without PCOS (n=40) and history of RM were recruited during their first antenatal visit from Al-Agoza Hospital, Cairo, Egypt. They were recruited during their first antenatal visit. Similarly pregnant women without PCOS (n=40) with no history of RM were recruited. Detailed demographic, medical and obstetric history was documented.
The inclusion criteria for the study were women aged 23 to 40 years at the time of enrolment into the study. The exclusion criteria for all participants included any other diagnosed medical condition link with increased risk of miscarriage, including thyroid status and gestational diabetes. All participants examined at the time of recruitment.
The control group were matched for age and BMI with no previous history of RM.
This study was conducted in line with the human experimentation guidelines, dictated by the Helsinki declaration. The procedures used were approved by local ethical committee and conducted in line with the practices of Al-Agoza Hospital, Cairo, Egypt. All patients within the study were briefed on the procedures and protocol that would take place and written consent was obtained before induction into the study.
- Methods
Confirmation of the pregnancy was made by beta-human chorionic gonadotrophin (Bhcg ) plus ultrasound scan and clinical history in case of miscarriage.
Diagnosis for patients with recurrent miscarriage was in concordance with the guidelines defined by the Royal College of Obstetricians and Gynaecologists; the loss of three or more consecutive pregnancies (Royal College of Obstetricians \& Gynaecologists 2011 ).The diagnosis of PCOS was based on Rotterdam 2003 Criteria (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004 ) which require two of the following; Oligo- or anovulation, Clinical and/or biochemical signs of hyperandrogenism or Polycystic ovaries and exclusion of other related disorders.
Blood Samples were collected by a professional trained in phlebotomy at the time points ; first, second and the third trimester or at the start of miscarriage .Samples were analysed for TT, SHBG,SHBG and DHEA using The ADVIA Centaur® XPT Immunoassay System - Siemens (https://www.siemens-healthineers.com/en-uk/immunoassay/systems/advia-centaur-xpt#TECHNICAL_SPECIFICATIONS).This system is easy to use where samples and reagents which could be loaded or without pausing the system. Also it doesn't require daily set up procedure and implement new assays immediately with one easy scan of a test definition bar code.
It requires 10-200 μL per test. it offers Automatic dilution varies by assay, up to 1:2500. The reagent capacity on board is 30 assays.
Similarly, cervical length was also measured at first, second and the third trimester or at the start of miscarriage .It was measured via transvaginal ultrasound (Berghella et al.,1997). The Voluson™ E8 ultrasound system is used for this study (https://www.gehealthcare.com/products/ultrasound/voluson/voluson-e8 ). The data was recorded by measuring the distance between the external os of the cervix and to where the cervix is closed defined by the apex of the funnelling of the membranes (Berghella et al., 1997) .
All patients within the RM groups attended cerclage treatment during the second trimester, this included elective and emergency elective procedures. Patients presented at the time of delivery or for recording of miscarriage where gestational age, gender of the fetus/baby and whether it was a live birth was noted.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 9 Months
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| PCOS-RM | – | Diagnostic Test: blood testPCOS women with history of RM |
| Non PCOS RM | – | Diagnostic Test: blood testNon PCOS women with history of RM |
| Control | – | Diagnostic Test: blood testwomen with no history of RM |
Who may qualify
- Ages
- 23 to 40 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Egyptian women
Key inclusion criteria (0 listed)
Key exclusion criteria (1 listed)
- Any other diagnosed medical condition link with increased risk of miscarriage, including thyroid status and gestational diabetes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| blood testblood sample is taken in first, second and third trimester of pregnancy | Diagnostic test | Control, Non PCOS RM, PCOS-RM |
Primary outcome
Cervical length changes during pregnancy
Time frame: 9 months
Cervical length is shorter in recurrent miscarriage groups at the start of the study and getting shorter during pregnancy
Androgens changes during pregnancy
Time frame: 9 months
TT, SHBG,DHEA and Sex Hormone Binding Globulin (SHBG) level were assessed at first, second and the third trimester or at the start of miscarriage
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2021.
- Individual participant dataSharing planned: Undecided. when study complited we will decide
Related trials for Polycystic Ovary Syndrome
Recruiting
Efficacy of Ovarian Drilling Via vNOTES Laparoscopy in Patients With PCOS
PCOS (Polycystic Ovary Syndrome)
RecruitingPhase 1
Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome
Anovulatory Infertility
RecruitingObservational study
The Value of LC-MS/MS Detection of Androgen Profiles in the Diagnosis of PCOS: A Prospective, Multicenter Real-world Study
Polycystic Ovary Syndrome (PCOS)
Recruiting
The Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome
PCOS (Polycystic Ovary Syndrome)
Recruiting
Brown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography
Polycystic Ovary Syndrome (PCOS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Essam El Mahdi, MD principal investigator
London Metropolitan University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Polycystic Ovary Syndrome, run by Kafrelsheikh University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cervical length changes during pregnancy (time frame: 9 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2021.